Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients

NCT01016912 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Infection

Interventions

DRUG: BMS-790052
DRUG: BMS-790052
DRUG: Placebo
DRUG: Peginterferon alfa-2b
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb